Crohn's Disease
Conditions
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit 2. Subject must be diagnosed with active Crohn’s disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology within the last year 3. Subjects with mild to moderate Crohn’s disease 4. All subjects must have a stool analysis negative for Clostridium difficile toxin, Yersinia enterolytica, Campylobacter jejuni, Salmonella, Shigella, within the 30 days prior to Visit 1. 5. Alls subjects must have had laboratory assessments within 7 days prior to visit 1 9. All subjects must weigh =15 kg at the time of enrolment. Are the trial subjects under 18? yes Number of subjects for this age range: 110 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Subjects who have had any previous intestinal resection proximal to and including the ascending colon 2. Subjects with evidence of severe active Crohn’s Disease and/or, structuring and prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications 3. Subjects who do not have a negative stool analysis, within the 30 days prior to Visit 1 4. Subjects who have been screened/or enrolled in this study previously within the last 6 months 16. Subjects taking 6-mercaptopurine or azathioprine should be on stable doses for 3 months prior to study start, and should plan on maintaining this stable dose throughout the course of the study 17. Subjects taking 5 aminosalicylates should be on stable doses 2 weeks prior to study start and should plan on maintaining this stable dose throughout the course of the study. 18. Subjects taking Methotrexate should be on stable doses 6 weeks prior to study start and should plan on maintaining this stable dose throughout the course of the study. 19. Subjects taking antibiotics for Crohn’s disease (e.g., ciprofloxan) should be on stable doses 2 weeks prior to study start. 21. Subjects taking Enteral Nutrition therapy for Crohn’s disease should be on stable regimen 2 weeks prior to study start and should plan on maintaining this regimen throughout the course of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: to investigate the safety of Entocort (budesonide) in a Paediatric population treated for mild to moderate Crohn’s disease;Secondary Objective: To characterize the disease activity in the trial population before and after treatment through the paediatric Crohn’s Disease Activity Index (PCDAI); Patient reported outcomes: Quality of Life with Entocort EC treatment based on a subject questionnaire (IMPACT 3);Primary end point(s): Safety measures such as adverse events, GCS-related side effects, HPA-axis measurement, laboratory test results and vital signs will be listed and summarized descriptively, with summaries including all subjects who received at least one dose of study treatment. Summaries will be produced by all patients and by dose group (6 mg or 9 mg).;Timepoint(s) of evaluation of this end point: end of 8 week treatment period. | — |
Countries
Canada, Germany, Italy, Poland, United States
Outcome results
None listed